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The role of lipids in providing energy and structural
cellular components during vertebrate development
is poorly understood. To elucidate these roles
further, we visualized lipid deposition and examined
expression of key lipid-regulating genes during ze-
brafish embryogenesis. We also conducted a semi-
quantitative analysis of lipidomic composition using
liquid chromatography (LC)-mass spectrometry.
Finally, we analyzed processing of boron-dipyrrome-
thene (BODIPY) lipid analogs injected into the yolk
using thin layer chromatography. Our data reveal
that the most abundant lipids in the embryo are
cholesterol, phosphatidylcholine, and triglyceride.
Moreover, we demonstrate that lipids are processed
within the yolk prior to mobilization to the embryonic
body. Our data identify a metabolically active yolk
and body resulting in a dynamic lipid composition.
This provides a foundation for studying lipid biology
during normal or pharmacologically compromised
embryogenesis.
INTRODUCTION
Lipids have significant roles in energy homeostasis, cellular
structures, and cellular signaling (Belkhou et al., 1991; Simons
and Ikonen, 1997; Spiegel et al., 1996). However, little is known
about the influence of lipid composition on vertebrate embryo-
genesis and development. Many animals, known as lecitho-
trophs, rely on maternally provided yolk for the nutrients and
energy needed for embryonic growth (Allen and Pernet, 2007).
Previous studies have established that maternally deposited
lipids within the yolk provide an energy source for the developing
organism and therefore considered the yolk as a nutrient reserve
without metabolic activity (Heras et al., 2000; Ho¨ltta¨-Vuori et al.,
2010; Rosa et al., 2005). Based on this, essential fatty acids and
other essential nutrients such as choline needed for structural
development were thought to be stored within the yolk cell and
mobilized when required (Wiegand, 1996). Individual vertebrateCell Roocytes and embryos have had their lipid content analyzed at
a single time point (Ferreira et al., 2010; Gonza´lez-Serrano
et al., 2013); the dynamics of lipid content were not studied dur-
ing development. A recent study by Guan et al. (2013) examined
the lipid profile of the fruit fly, Drosophila melanogaster, during
embryonic, pupal, larval, and adult stages. While this study pro-
vided insight into lipid requirements, triglyceride usage, and
changes in sphingolipids during fruit fly development, the focus
of their study was membrane lipids in a non-vertebrate animal,
and the authors were unable to discriminate between the yolk
lipid reserve and lipids present in the body of the embryo
(Guan et al., 2013). Cumulatively, these studies have provided
a broad picture of the roles of lipids and their importance during
development, but a comprehensive understanding of the com-
plex remodeling of lipids within vertebrate development requires
further study.
The zebrafish (Danio rerio) is a vertebrate model organism that
has been intensively used to study developmental biology and
human diseases (Dawid, 2004; Zon, 1999). Recently, zebrafish
have been used to study various aspects of lipid biology
including lipidmetabolism, the genes regulating lipid processing,
and the roles of lipids in diseases (Carten et al., 2011; Flynn et al.,
2009; Schlegel and Stainier, 2006). Importantly, many properties
of lipid biology present in zebrafish are conserved in humans.
Homologous genes regulating lipid metabolism are found in ze-
brafish and they share a similar lipid and lipoprotein metabolism
to that of humans (Miyares et al., 2014; Schlegel and Gut, 2015;
Schlegel and Stainier, 2006; Thisse et al., 2001; Thisse and
Thisse, 2004). This homology has allowed researchers unprece-
dented insight into disease pathology including atherosclerosis,
non-alcoholic fatty-liver disease, and obesity (Fang et al., 2014;
Flynn et al., 2009; Schlegel, 2012).
The zebrafish is a lecithotrophic organism (discussed in Kunz-
Ramsay, 2013), relying on a yolk contents for nutrition
throughout development until an early larval stage, at5 days
post fertilization (dpf), when it can commence feeding. Because
of this reliance on a yolk, zebrafish embryos can be considered a
‘‘closed system,’’ meaning that their nutrient intake is uninflu-
enced by outside factors. Therefore, potential experimental vari-
ables due to feeding can be eliminated during embryogenesis.
The zebrafish is amenable to a variety of techniques for studying
metabolism during development including pharmacologicaleports 14, 1317–1329, February 16, 2016 ª2016 The Authors 1317
Figure 1. Lipid Distribution and Metabolic Gene Expression throughout Embryogenesis
(A–E) Bright field images show yolk utilization from 0 hpf to 5 dpf.
(F–I) ORO staining shows that there were no deposits of neutral lipid in the head of the embryo at 24 hpf (F), but lipid was present at 48 hpf in the forebrain
(arrow, G) and around the eye and underneath the otic vesicle (arrowhead, G), at 72 hpf around the eye (arrowhead, H), and at 5 dpf at a low amount (I).
(J) c/ebpa expression was present at 24 hpf in the developing liver and gut (arrowhead).
(K–M) c/ebpa expression increased in these organs from 48 hpf to 5 dpf (arrowhead).
(legend continued on next page)
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inhibition of key proteins involved in lipid biology (Nishio et al.,
2008, 2012).
Additional benefits of the zebrafish as a model are that it
develops externally from the mother and embryos undergo dis-
coidal, meroblastic cleavage, a process that separates the
developing embryo from the yolk reviewed by Gilbert (2000).
This separation is established by a multinucleated cell layer
called the yolk syncytial layer (YSL) (Kimmel and Law, 1985)
(see Figure S1 for details). These features allow for easy dissoci-
ation of the yolk and body of the embryo enabling lipid measure-
ments of the two independently. This provides the opportunity to
compare lipid dynamics not only with respect to time, but also
between the source (yolk) and its destination (body). Here, we
have examined the dynamic properties of lipidmolecular species
composition, abundance, location, and genetic regulation
throughout zebrafish embryogenesis (0–72 hpf) and early larval
stages (72–120 hpf). We performed lipidomic analyses to
observe changes of 365 individual lipid species, which were
grouped into 24 lipid classes and subclasses, within both the
yolk and body during zebrafish development. Additionally, we
pharmacologically inhibited a crucial nuclear receptor (PPARg)
implicated in lipid metabolism (Ferre´, 2004) and studied the
changes in lipidomic profile. Furthermore, by using fluorescently
labeled lipid analogs BODIPY, we were able to identify the yolk
as a site of active lipid metabolism. These analyses have pro-
vided an unprecedented examination into the progression of lip-
idomic composition and metabolism in a developing vertebrate
organism revealing active lipid remodeling in the yolk prior to
reaching the embryo proper.
RESULTS
Progression of Zebrafish Gene Expression and Lipid
Localization during Embryogenesis
Lipidomic analyses were performed at different stages of zebra-
fish development, at the 1 cell stage or 0 hr post fertilization (hpf)
(fertilized embryo, Figure 1A), at 24 hpf, the latest timing of somi-
togenesis (Figure 1B), during organogenesis at 48 and 72 hpf
(Figures 1C and 1D) and during early larval development, soon
before zebrafish become free feeding larvae, and at 5 dpf and
do not solely rely on yolk reserves anymore (Figure 1E). Note
that the size of the yolk contents decreased as embryonic devel-
opment progressed. Zebrafish were stained with Oil-Red-O
(ORO), to label neutral lipids, at the same developmental stages.
At 24 hpf, the body was mostly stain-free (Figure 1F). By 48 hpf,
stain was present in the forebrain, around the eye, and under-
neath the otic vesicle (Figure 1G), and increasingly in the vascu-
lature (not shown). At 72 hpf, the stain had increased in these
regions and was also detected in the pharyngeal arches, which
will later form the gills (Figure 1H). By 5 dpf, the stain decreased
throughout the entire body of the embryo, but trace amounts(N–Q) fabp11a expression was located in the forebrain (arrow), in the eye and in
(R–U) lpl was present in the developing liver (arrowhead) from 24 to 5 dpf.
(V) pparg was not detected in the embryo at 24 hpf.
(W and X) At 48 and 72 hpf, pparg was expressed in the developing gut (arrowhe
(Y) At 5 dpf, expression increased in the liver (arrow) and gut (arrowhead) and w
See also Figure S1.
Cell Rwere still present (Figure 1I). Note that the intensity of ORO stain-
ing gradually decreased in the yolk as time progressed, meaning
that less neutral lipid was present in the yolk and that most of
these lipids had either been used by the embryo or stored in
the embryo body. Whole-mount in situ hybridization (WISH)
was performed, at the same time points, using mRNA antisense
probes for genes that are known to be integral to the activities of
lipid metabolism, lipid processing, and lipid mobilization,
including the pre-adipocyte marker CCAAT/enhancer-binding
protein alpha (c/ebpa), the lipid transport protein fatty acid bind-
ing protein 11a (fabp11a), the lipid processing protein lipoprotein
lipase (lpl), and a key adipocyte transcription factor peroxisome
proliferator-activated receptor gamma (pparg). c/ebpa was
expressed at 24 hpf in the liver and gut anlage and in the YSL
(Figure 1J). Expression continued to increase in these devel-
oping organs at all later time points (Figures 1K–1M). Note that
in situ hybridization performed using a sense probe for c/ebpa
or pparg does not stain the developing gut (Figure S1). fabp11a
was present in the forebrain, in the eye, and in the hindbrain at
24 hpf (Figure 1N). At 48 hpf, the expression increased
throughout the head and remained present at these locations
at 72 hpf and 5 dpf (Figures 1O–1Q). lpl mRNA was located in
the liver primordium at 24 hpf (Figure 1R). lpl expression gradu-
ally increased in the liver as embryogenesis progressed (Figures
1S–1U). pparg was not detected at 24 hpf (Figure 1V). At 48 hpf
and 72 hpf, expression was located in the developing gut (Fig-
ures 1W–1X). By 5 dpf, pparg expression was strongly detected
in the liver, the gut, and swim bladder (Figure 1Y). The evolving
and expanding expression patterns of these genes appear to
increase throughout development, but also match the initial in-
crease in lipid abundance as detected by ORO.
Temporal Changes of Lipid Classes during Zebrafish
Development
In order to discern changes of lipid abundance relative to the yolk
and body separately, the two were manually dissected out and
analyzed independently (absolute amounts of each lipid species
at all time points are listed in Table S1). At 0 hpf, which was
considered to be an initial reservoir of lipid for embryonic devel-
opment, the major lipids present were both polar and non-polar
lipids, and in order of decreasing abundance, these were choles-
terol (COH), phosphatidylcholine (PC), triacylglycerol (TG),
phosphatidylinositol (PI), phosphatidylethanolamine (PE), diacyl-
glycerol (DG), cholesteryl esters (CE), and sphingomyelins (SM)
(Figure 2A). Cholesterol was the most abundant at 0 hpf and
accounted for 40% of the total lipids, while PCs were 17%,
TGs were 9%, PIs were 8%, PEs were 5%, DGs were 4%, CEs
were 3%, and SMs were 3%. Other lipid classes that were
detected in the yolk sac at lower concentrations included
phosphatidylserine (PS), phosphatidylglycerol (PG), the ether
linked lipids and plasmalogens, alkylphosphatidylcholinethe hindbrain (arrowhead) from 24 hpf to 5 dpf.
ads).
as present in the swim bladder. E, eye; G, gut; L, liver; Y, yolk.
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Figure 2. Lipid Category Profile of Zebrafish Embryo Yolks and Bodies throughout Embryogenesis
(A–E) The lipid composition of whole zebrafish embryos at 0 hpf (A), of yolks at 24 hpf (B) and 5 dpf (C) and bodies at 24 hpf (D) and 5 dpf (E) are depicted by lipid
category percentages relative to the amounts of total lipids detected.
(F–K) Amounts of individual lipid categories for both yolks and bodies are displayed at 0, 24, 48, 72, and 120 hpf for the six most abundant lipid categories: TG (F),
COH (G), DG (H), CE (I), PC (J), and PE (K). Lipid species concentrations are shown in pmol/15 embryos.
See also Figure S2 and Table S1.(PC-O), alkenylphosphatidylcholine (PC-P), alkylphosphati-
dylethanolamine (PE-O), and alkenylphosphatidylethanolamine
(PE-P). We also observed the lysophospholipids, lysophosphati-
dylethanolamine (LPE), lysophosphatidylcholine (LPC), lysoal-
kylphosphatidylcholine (LPC-O), and lysophosphatidylinositol
(LPI) as well as the sphingolipids, dihydroceramide (dhCer),
ceramide (Cer), monohexosylceramide (MHC), dihexosylcera-
mide (DHC), trihexosylceramide (THC), and GM3 ganglioside
(GM3) (Figure 2A). Most yolk lipids decreased in absolute
amounts with increasing days after fertilization, with a majority
of those lipids essentially showing a fairly linear decrease. Sur-
prisingly, three lipids showed a rise in concentration between
0 and 24 hpf and then a linear decrease: TG and PC (Figures
2F and 2J) and LPE (Figure S2P). Interestingly, the DG content
was maintained at a constant level throughout development
(Figure 2H).
In the body, most of the lipid groups referred to for the yolk
were present but in low absolute amounts at 24 hpf, with the
exception of two of the phospholipids (PC and PE) that were in
higher concentration relative to the amount in the yolk at
24 hpf (Figures 2J and 2K). The following body lipids increased
in concentration steadily from 24 to 120 hpf: COH, DG, CE, PE,
PS, SM, PG, GM3, and dhCer with a slight increase with time
for PC (Figures 2G–2K). Relatively low and stable concentrations
were detected through time for PI and TG (Figures 2E and 2 F). At1320 Cell Reports 14, 1317–1329, February 16, 2016 ª2016 The Auth5dpf, the four major lipid groups in the body were COH (39%),
PC (15%), DG (10%), and PE (8%), while the other lipid classes
were present at lower concentrations (Figure 2E). A complete
analysis of the concentration of the 24 lipid classes throughout
development in both the yolk and the body can be found in
Figure S2.
Temporal Dynamics of Lipid Species Composition
When comparing the molecular species showing the highest
levels within a class, it was clear there were two distinct patterns:
(1) molecular species that were the most abundant within a lipid
class, which were the same in the yolk and in the body, and
(2) molecular species that were the most abundant within a lipid
class, which were not the same in the yolk and in the body as
measured by mass spectrometry. Group one consisted of the
lipid species PE 40:6, LPE 22:6, PE-O 40:6, PC 34:1, LPAF
16:0, PC-O 38:5, PI 38:6, PS 40:6, PG 16:0-18:1, dhCer 16:0,
DHC 16:0, GM3 16:0, SM 34:1, LPC 22:6, and TG 16:0-16:
0-18:1. Within group two, the most abundant lipids in the yolk
were PE-P 16:0-22:6, PC-P 40:5, Cer 24:1, CE 20:5, MHC
24:1, and DG 16:0-18:1, whereas in the body the most abundant
were PE-P 16:0-22:5, PC-P 38:5, Cer 16:0, CE 16:0, MHC 16:0,
and DG 16:0-22:6 (not shown).
To reveal the lipid changes during development, the abun-
dance of an individual lipid species was displayed as a relativeors
change compared to an average level of the specific species
across the time intervals, visualized as a heat map. The heat
map reveals that most of the lipid species within the yolk sac
decreased over time, while most of them increased within the
body (Figure S2). It also reveals that many of the TG lipid species
reached their highest relative amount at 72 hpf and dropped
below the mean at 120 hpf. The same holds true for some DG
and PC species (Figure S2). This fits well with our observation
that ORO staining was the strongest in the embryos body at 48
and 72 hpf and decreased at 120 hpf (Figures 1G–1I), as ORO
stains for neutral lipids including TG. Within the yolk, at the
one-cell stage, LPE species 16:1-0:0 and 18:2-0:0 were lower
than their mean abundance and they increased to high points
at 72 hpf and 120 hpf, respectively. GM3 20:0, 22:0, and 24:0
were not present in the yolk, but were detected in the body.
These species rose in a steep linear increase within the body
as they were six times, ten times, and 19 times more abundant,
respectively, at 120 hpf than they were at 24 hpf. GM3 16:0,
which was present in both the yolk and body, increased by 16
times within the body from 24 to 120 hpf (not shown).
Interestingly, not all lipid species decreased within the yolk
from 0 to 24 hpf. There were 77 (out of the 332 detected, 23%)
lipid species that significantly increased (p < 0.05, using one-
way ANOVA and Tukey HSD; see Experimental Procedures) in
absolute amount during this developmental period (Table S2).
Many of these lipid species were in the TG andPC classes, which
showed overall increases in this interval. Notably, TG 18:0-18:
0-18:0 increased by more than three times, while TG 14:
0-16:0-18:2, 14:0-16:1-18:2, 14:0-18:0-18:1, and 16:1-16:1-16:1
all increased by at least 60% in absolute amount. PC 30:0, 32:2,
and 33:0 increased bymore than 50%within the yolk from0 to 24
hpf. Lipid species in classes other than TG and PC increased as
well. CE 20:0 increased by 90%. LPC 14:0 increased by more
than three times, while LPC 15:0, 18:2, and 20:4 all increased
by more than 50%. Cer 20:0 was 57% higher at 24 hpf in the
yolk than at 0 hpf. It should be noted that these lipids are present
in the yolk at varying relative percentages, and the impact of their
increases may depend on their absolute abundances. It is of in-
terest to note that in this period, many of the significant increases
were in either saturated or monounsaturated species, the mean-
ing of which is not clear. The trend of increasing lipid species in
the yolk did not continue throughout embryonic and larval
stages. The increase of lipid species amounts during the first
day of development indicates that lipid metabolic processes
were occurring in the yolk. However, the number of lipid species
that significantly increased during the second day was only
seven species.
Fluorescent Lipid Analog Incorporation Reveals a
Metabolically Active Yolk Cell
We speculated that the increases in lipids within the yolk were
due to an active role of the yolk cell in lipid processing. To
confirm this hypothesis, we injected BODIPY-labeled fluores-
cent lipid analogs into the yolk and followed their incorporation
into lipids at different time points post injection. We injected a
free fatty acid (FFA) analog, which could be rapidly incorporated
into newly synthesized neutral lipids and phospholipids and a PC
analog, to mimic endogenous PC metabolism. Embryos wereCell Rinjected in the center of the yolk cell with approximately 5 nl of
a BODIPY analog diluted in olive oil solution (1 mg/ml) at
24 hpf. The injected droplets diffused rapidly, noticeably
spreading from the injection droplet by 1 hr post injection (hpi)
(Figures 3A and 3D), and continued to diffuse throughout the
yolk at later time points, observed up until 6 hpi (Figures 3B
and 3E).
Incorporation of lipid analogs was determined by extracting
lipids from yolks and embryo bodies separately. Lipid extracts
were then run on a thin layer chromatography (TLC) plate and
monitored for fluorescent bands. We screened for incorporation
at 1 hpi, 3 hpi, and 6 hpi in yolks and bodies (Figures 3C and 3F;
see also Figure S3 for non-overplayed plates). In FFA-injected
embryos, fluorescence was detected in yolk sample bands
that correlated to TG standards as early as 1 hpi (Figure 3C,white
arrowheads). Notably, these bandswere absent in body samples
at 1 hpi and 3 hpi, but a TG band was detected in the embryo
body sample at 6 hpi (Figure 3C, asterisk). Additionally, there
were bands below these TGbands (Figure 3C, open arrowheads)
that followed a similar pattern, in that they were present in yolk
samples at each time point and only detected in the bodies at
6 hpi (Figure 3C, pound sign). Furthermore, there were groupings
of four bands present in yolk samples at 1 hpi and 3 hpi (Fig-
ure 3C, brackets); whereas there was only one band present in
the corresponding location in the 1 hpi and 3 hpi body samples
(Figure 3C, cross). At 6 hpi, a new band was detected both in
the yolk sample and body (Figure 3C, circles).
Newly incorporated fluorescent bands were detected in PC
analog injected embryos (Figure 3F). Two bands were present
in yolk samples at 1 hpi, 3 hpi, and 6 hpi (Figure 3F, arrows;
parentheses) in an area between the FFA and TG lipid standards
that were never detected in body samples. Additionally, there
was a band present in the yolk samples at all time points (Fig-
ure 3F, red arrowheads), which was located close to the position
of the DG lipid standard and was not detected in any body
samples.
Incorporation of the fluorescent lipid analogs within the yolk,
as evidenced by the detection of fluorescent bands, demon-
strates that the yolk cell is a site of active lipid metabolism, pro-
ducing newly formed lipids prior to mobilization into the body.
Note that uninjected yolks showed no fluorescent bands (Fig-
ure S3). These results explain our observation of increased abun-
dance of some lipid species within the yolk between 0 and 24 hpf
(Figures 2, 3, and S2). We concluded from these injection exper-
iments that lipidmetabolism is occurring in the yolk prior tomobi-
lization to the body. Our data also demonstrate that different
lipids are mobilized at different paces from the yolk to the
embryo body. This demonstration that the yolk cell is metaboli-
cally active in lipid processing may explain the detection of
several lipid metabolizing enzymes in the yolk or YSL throughout
development (Table 1; see also Table S3 for list of lipid meta-
bolism gene expressed during zebrafish embryogenesis).
PPARg Inhibition Modifies Lipid Accumulation in the
Developing Embryo
PPARg is a nuclear receptor transcription factor that is a major
component in the development of adipocytes and is highly
involved in lipid metabolism (Ferre´, 2004; Rosen et al., 1999;eports 14, 1317–1329, February 16, 2016 ª2016 The Authors 1321
Figure 3. BODIPY-Labeled Lipid Injections Were Incorporated into New Lipids in the Yolk Sac
(A, B, D, and E) BODIPY-labeled FFA and PCwere injected into yolk sac of the embryos at 24 hpf. Fluorescent imaging shows spreading of fluorescent FFA (A) and
PC (D) at 1 hpi (as marked by dotted white lines) that continued to spread throughout the yolk sac at 6 hpi (B and E).
(C) TLC of BODIPY-labeled FFA injections, with lipid standards in pale orange, shows fluorescent bands in yolk sac samples at 1, 3, and 6 hpi (white arrowheads)
and a band at 6 hpi in the body sample (asterisk) that correspond to the TG standard. Bands below the TG bands are present in yolk sac samples at 1, 3, and 6 hpi
(open arrowheads) while a similar band is only detected at 6 hpi in the body sample (pound sign). Groupings of four bands, just above the cholesterol standard,
were present in yolk samples at 1 hpi and 3 hpi (brackets). One band only was detected in the adjacent area in body samples at 1 hpi and 3 hpi (cross). At 6 hpi,
another band is detected above these bands in both the yolk sac and body samples that were not present at earlier time points (circle) demonstrating a temporal
dynamic evolution of lipid during development.
(F) TLC of BODIPY-labeled PC injections produced a pair of bands between the TG and FFA standards only in the yolk sac samples at 1, 3, and 6 hpi (arrows,
parentheses). These bands were never detected in the body up to 6 hpi. Bands that were located at a level consistent with the DG standard were detected in yolk
sac samples at 1, 3, and 6 hpi (red arrowheads) but were never observed in the body up to 6 hpi.
See also Figure S3.Tontonoz and Spiegelman, 2008). Therefore, we decided to
investigate the changes in lipid profile in embryos where PPARg
function had been pharmacologically inactivated. In order to do
this, we exposed zebrafish embryos to bisphenol A diglycidyl
ether (BADGE) as previously described (Song et al., 2009), which
binds to the PPARg receptor and blocks its activity (Wright et al.,
2000). Treatments of zebrafish embryos from 26 hpf to 52 hpf
with 5 mM BADGE reduced ORO stain throughout the body of
the embryo and notably in the head (Figures 4A and 4B). BADGE
exposure also reduced the expression of c/ebpa and lpl when
embryos were treated from 50–72 hpf (Figures 4C–4F). BADGE
did not affect the expression of pparg at 72 hpf (Figures 4G
and 4H). Inhibiting PPARg activity was associated with a slight
but reproducible increased expression of fabp11a in zebrafish
embryos (Figures 4I and 4J).
Since we observed decreased ORO stain and expression of
c/ebpa and lpl in BADGE-treated embryos, we wanted to
analyze changes that PPARg inhibition would cause on the lipid
profiles of the developing embryos. Therefore, zebrafish em-
bryos were treated with 5 mM BADGE from 26 hpf to 52 hpf,
were euthanized, and had the yolks and bodies manually
separated (in a similar fashion as presented above). Liquid
chromatography (LC)-mass spectrometry was performed on
BADGE-treated and control samples to measure the amounts1322 Cell Reports 14, 1317–1329, February 16, 2016 ª2016 The Authof specific lipid species. The lipidomic analysis revealed that
more than one-quarter (25.9%) of lipid species present in control
(untreated) bodies were significantly changed in the BADGE-
treated bodies (using Tukey HSD). Among the lipid species
that were most affected were lysophospholipid species, where
PPARg receptor inhibition increased the concentration of many
of the LPCs, LPAFs, and LPEs (Figure 4K). Of the 18 LPCs that
were identified, 17 showed an increase of at least 1.48 times
the control amount. Five out of the six detected LPAFs were
higher than the control (Figure 4K), with the species PC-O
18:0-0:0 at more than two times the amount in the control sam-
ples. The dihydroceramides also increased in BADGE-treated
embryo bodies, particularly dhCer 18:0, which increased almost
eight times compared with control. While most of the phospha-
tidylcholine species remained unchanged, two species
increased significantly; PC 35:4 was almost twice as high and
PC 18:2-20:4 was more than 2.5 times higher than the control
(Figures 4K and 4L).
In addition to the increases in lipid species, many lipid species
decreased in the body in BADGE-treated embryos relative to
control amounts. The PC-O and PC-P classes showed a general
trend of decreasing. PC-O species 36:5, 38:4, 40:6, and 40:7 all
decreased by more than 30% (p < 0.05) compared with the con-
trol level, whereas 5 out of the 16 PC-P species analyzed showedors
a decrease of at least 25% (p < 0.05). While the PE-O lipids did
not show a decrease overall, specific lipid species were notice-
ably decreased, including PE-O 18:2/18:2 and PE-O 34:1, which
were reduced by more than 20% (p = 0.071, p < 0.05 respec-
tively). The PE-P species also had a consistent trend of
decreasing. Six out of ten PE-P species showed a significant
decrease compared with control (Figures 4K and 4L). For a com-
plete analysis of lipid class changes in BADGE-treated embryos,
see Figure S4.
DISCUSSION
In order to provide insight into fundamental lipid properties, we
performed lipidomic analysis throughout embryogenesis in a
vertebrate organism. To understand the temporal changes in
the lipidomic profile of the embryo’s body, we measured lipids
in the yolk and body separately. This allowed for observation
of the dynamic profile of lipids. For example, we observed that
the absolute amount of TG amount increased in the yolk from
0 to 24 hpf and then steadily declined. Unexpectedly, in the
body, TG only increased a little relative to the amount in yolk (Fig-
ure 2F). The low level of TG was probably due to it immediately
being used as an energy source upon transfer from the yolk to
body. The low relative abundance of TG that we detected in
the body at 120 hpf (Figure 2E) fits with a previous report of a
relatively low percentage of TG in whole larvae at 6dpf (Miyares
et al., 2014).
Measurement of DG revealed a different trend in lipid utiliza-
tion. Although the amount of DG increased in the body as
embryogenesis progressed, a basal level of DG was maintained
in the yolk. As DGs are important in cellular signaling (Spiegel
et al., 1996), it is possible that maintaining a consistent level of
DG is necessary to sustain proper trafficking within the yolk.
However, the secondary signaling role of DG may only require
low amounts of the lipid and therefore could not account for
the quantities that we have observed. DG is an intermediate in
the anabolism and catabolism of TG and phospholipids including
PC, PE, PI, and PS (Choi et al., 2004; Gibellini and Smith, 2010).
Therefore, it is possible that a relatively consistent level of DG is
maintained because it was used and produced at the same rate
within the processing of metabolic pathways. We noted that
while PC increased in absolute amounts in the body from 24 to
120 hpf, it did not increase as sharply as other putative cellular
membrane lipids. The level of PC that we detected in the body
at 120 hpf, while relatively abundant at 15% of the total lipid (Fig-
ure 2E), was not as high as the 32.9% that was reported at 6 dpf
(Miyares et al., 2014). This difference was probably due to the
PC contained in the yolk that was measured by the latter
experiment.
Lipid transport from the yolk to body is poorly understood. Our
data reveal a previously unidentified role of the yolk cell in active
metabolism of lipids prior to transfer into the body.Wemeasured
an increase in nearly one-fourth of lipid species from 0 to 24 hpf
(Table S2), including many in TG and PC classes, as well as spe-
cific lipids in other classes. Additionally, we observed that exog-
enous FFA and PC lipid analogs were incorporated into TG and
DG lipids, respectively, in the yolk prior to detection in the body.
Furthermore, there was incorporation of both analogs into multi-Cell Rple other unidentified lipids. Our gene expression literature
search (Table 1) identified that at least three elongations of
very long chain fatty acids (elvol) genes are expressed in the
yolk or YSL. These elongase enzymes lengthen fatty acids prior
to anabolism of more complex lipids (Jakobsson et al., 2006).
Phospholipase A2 and phospholipase D2 were also found to
be expressed in the yolk. Both lipases play roles in processing
phospholipids, breaking them down into constituent groups
(Jang et al., 2003; Ravaux et al., 2007). These enzymes, along
with presumably other metabolic enzymes yet to be found ex-
pressing in the yolk, likely act to process the maternally depos-
ited yolk lipids before they are transported into the body. This
lipid processing could explain the increases in lipids from 0 to
24 hpf and incorporation of fluorescent lipid analogs within the
yolk and demonstrate the yolk cell as a site of metabolic activity.
Further processing and transport of lipids continues in the YSL
(Figure S1). Lipids are mobilized to this tissue from granules in
the yolk cell, where they can be packaged into lipoproteins
and circulated throughout the body (Ho¨ltta¨-Vuori et al., 2010;
Schlegel and Stainier, 2006). By 24 hpf, blood circulation has
begun in the zebrafish and is concurrent with the earliest pres-
ence of ORO stain that we detected in the vasculature in our em-
bryos. Furthermore, the caudal vein is in direct contact with the
YSL at this time (Figure S1). This indicates that circulation may
further provide the means to deliver high quantities of lipid
throughout the body. Additional lipid transport and processing
could occur in the pharynx of the embryo starting around
48 hpf. This structure is located in close proximity to the YSL
and yolk (Figure S1). Furthermore, gene expression of adiponec-
tin, the adiponectin receptor, and the leptin receptor in the
pharyngeal region has led others to propose that it could play
a role in incorporating yolk nutrients into the body (Lampert
et al., 2003; Nishio et al., 2008). This idea is supported by the
localized expression of phospholipase C, beta 3, phospholipase
D1a, high density lipoprotein binding protein a, fatty acid binding
protein 3, and several other lipid metabolism-related genes
(Table S3). At 4 dpf, lipids have been observed to accumulate
in the lumen of the gut (Miyares et al., 2014). Furthermore,
by this time, multiple cell types required for digestion are differ-
entiated and present in the intestine (Wallace et al., 2005). It is
interesting to speculate that lipids may be processed in the gut
before feeding has commenced. By 5 dpf, the yolk has predom-
inantly been used up and the zebrafish begins feeding. Taken
together, these data indicate, unlike previously speculated,
that the yolk cell is not only a nutrient reserve but it also plays
an active role in lipid transformation prior to transport into the
embryo’s body.
Having developed a comprehensive understanding of the
changes in lipid composition in the zebrafish during develop-
ment, it is now possible to use the model to study various as-
pects of lipid metabolism and its regulation. We postulated
that inhibition of PPARgwould cause a change in the lipid profile
of the embryo as PPARg is highly involved in adipogenesis
(Rosen et al., 1999). A notable effect of BADGE treatment on
the embryos was an increase in lysophospholipid species.
In a previous study, a PPARg chemical agonist was
shown to decrease the mRNA expression and activity of phos-
pholipase A2 in cultured rat vascular smooth muscle cellseports 14, 1317–1329, February 16, 2016 ª2016 The Authors 1323
Table 1. Lipid-Associated Genes Expressed in the Yolk of Zebrafish
Gene Name (Zebrafish Gene Abbreviation) Known Function Timing of Expression in Zebrafish References
Phospholipase A2, group XIIB
(pla2g12b)
phospholipase A2 enzymes hydrolyze ester bonds of
glyceroacylphospholipids to produce lysophospholipids
and nonesterified fatty acids (Ravaux et al., 2007)
50% epiboly-5 dpf Thisse and Thisse, 2004
Phospholipase B domain
containing 1 (plbd1)
unknown 50% epiboly-60 hpf Thisse and Thisse, 2004
Phospholipase D2 (pld2) phospholipase D hydrolyzes phosphatidylcholine to generate
phosphatidic acid (PA) and choline (Jang et al., 2003)
50% epiboly-10 hpf, 4–13 dpf Liu et al., 2010
Thisse and Thisse, 2004
Patatin-like phospholipase domain
containing 7b (pnpla7b)
unknown one cell-72 hpf Thisse and Thisse, 2004
Apolipoprotein A-Ia (apoA-Ia) apolipoprotein A-I is the major protein component of high
density lipoprotein in plasma (Schonfeld and Pfleger, 1974)
6 hpf-72 hpf, adult Babin et al., 1997
Thisse et al., 2001
Apolipoprotein A-II (apoA-II) apolipoprotein A-II is the second most abundant protein of the
high density lipoprotein particles (Schonfeld et al., 1977)
four cell-72 hpf, adult Thisse et al., 2001
Cheng et al., 2006
Zhang et al., 2011
Apolipoprotein A-IVa (apoA-IVa) apolipoprotein A-IV is a key protein component of
chylomicrons (Wang et al., 2013)
50% epiboly-60 hpf Thisse and Thisse, 2004
Apolipoprotein A-IV b, tandem
duplicate 1 (apoA-IVb.1)
50% epiboly-5 dpf, adult Thisse and Thisse, 2004;
Levi et al., 2012
Apolipoprotein A-IV b, tandem
duplicate 2 (apoA-IVb.2)
two cell-5 dpf Rauch et al., 2003
Apolipoprotein Ba (apoBa) apolipoprotein B is the primary apolipoprotein of chylomicrons
and low-density lipoproteins (Kane et al., 1980; Knott et al., 1986)
50% epiboly-60 hpf, adult Thisse and Thisse, 2004;
Cheng et al., 2006
Apolipoprotein Bb, tandem
duplicate 1 (apoBb.1)
50% epiboly-60 hpf, adult Thisse and Thisse, 2004
Apolipoprotein Ea (apoEa) apolipoprotein E is a class of apolipoprotein found in the chylomicron
and LDLs. It is important in lipoprotein receptor binding (Mahley, 1988)
50% epiboly-60 hpf Thisse and Thisse, 2004
Apolipoprotein Eb (apoEb) 128 cell-5 dpf, adult Thisse and Thisse, 2005
Microsomal triglyceride transfer
protein (mtp)
MTP combines TG, cholesterol esters of fatty acids,
free cholesterol, and phospholipids with apolipoprotein B
to form chylomicrons (Schlegel and Stainier, 2006)
one cell-5 dpf, adult Thisse and Thisse, 2004;
Marza et al., 2005
ELOVL fatty acid elongase 2 (elovl2) ELOVLs are involved in fatty acid synthesis by elongating
fatty acid chains (Jakobsson et al., 2006)
one cell-5 dpf, adult Monroig et al., 2009
ELOVL fatty acid elongase 5 (elovl5) one cell-60 hpf, adult Thisse and Thisse, 2004
Monroig et al., 2009
ELOVL fatty acid elongase 6 (elovl6) 50% epiboly-60 hpf Thisse and Thisse, 2004
Fatty acid binding protein 1b,
tandem duplicate 1 (fabp1b.1)
fatty acid binding proteins regulate fatty acid
transport (Chmurzynska, 2006)
10 hpf-5 dpf, adult Sharma et al., 2006
24-Dehydrocholesterol reductase
(dhcr24)
DHCR24 is an oxidoreductase that catalyzes the reduction of the
delta-24 double bond of sterol intermediates during cholesterol
biosynthesis (Waterham et al., 2001)
50% epiboly-60 hpf Thisse and Thisse, 2004
Delta(4)-desaturase,
sphingolipid 1 (degs1)
DEGS1 converts dhCer into Cer (Ruangsiriluk et al., 2012) 50% epiboly-60 hpf Thisse and Thisse, 2004
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Table 1. Continued
Gene Name (Zebrafish Gene Abbreviation) Known Function Timing of Expression in Zebrafish References
Arylsulfatase A (arsa) arylsulfatase A is an enzyme that hydrolyzes the sulfate ester bond of
cerebroside 3-sulfate, a component of the myelin sheath, to produce
cerebroside and sulfate (Lukatela et al., 1998)
one cell-72 hpf Thisse and Thisse, 2004
Sphingomyelin phosphodiesterase 2a
(smpd2a)
SMPD2 is responsible for breaking sphingomyelin down into
phosphocholine and ceramide (Ago et al., 2006)
50% epiboly-60 hpf Thisse and Thisse, 2004
Acyl-CoA synthetase long-chain family
member 4a (acsl4a)
ACSL enzymes convert free fatty acids to fatty acyl-CoAs as the initial
step in a majority of processing events (Miyares et al., 2014)
four cell-4 dpf Miyares et al., 2014
Acyl-CoA synthetase long-chain family
member 4b (acsl4b)
50% epiboly-60 hpf Thisse and Thisse, 2004
Enoyl-CoA, hydratase/3-hydroxyacyl-CoA
dehydrogenase (ehhadh)
this enzyme catalyzes the metabolism of fatty acids to produce
acetyl-CoA and energy (Bahnson et al., 2002)
one cell-72 hpf, adult Thisse and Thisse, 2004
Acyl-CoA synthetase long-chain family
member 1b (acsl1b)
all ACSLs convert long-chain fatty acids into acyl-CoA
(Soupene and Kuypers, 2008)
50% epiboly-60 hpf Thisse and Thisse, 2004
Acyl-CoA synthetase long-chain family
member 5 (acsl5)
one cell-60 hpf Thisse and Thisse, 2004
ATP-binding cassette transporter
(abca1b)
ABCA1 is a cholesterol and phospholipid transporter in conjunction
with Apolipoprotein A-I (Wang et al., 2001)
50% epiboly-5 dpf Thisse and Thisse, 2004
Scavenger receptor class b, member 1
(scarb1)
SCARB1 acts as a receptor for HDL and may influence its
plasma levels (Rigotti et al., 1997)
50% epiboly-19 hpf Thisse and Thisse, 2004
Cholesteryl ester transfer protein (cetp) CETP is an enzyme that mediates the exchange of lipids
between lipoproteins (Kuivenhoven et al., 1998)
50% epiboly-5 dpf Thisse and Thisse, 2004
ORMDL sphingolipid biosynthesis
regulator 3 (ormdl3)
ORMDL3 may regulate ceramide biosynthesis, but its function
is still unknown (Siow and Wattenberg, 2012)
one cell-72 hpf Thisse and Thisse, 2004
List of genes expressed in the yolk sac, their know function, and their timing of expression.
See also Tables S2 and S3.
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Figure 4. The Effects of PPARg Inhibition on the Lipid Profile and Gene Expression of Zebrafish Embryos
(A and B) ORO staining showed decreased lipid present in embryos treated with 5 mM BADGE from 26–52 hpf (B) compared with controls (A).
(C–J) Treatment with 5 mM BADGE from 50–72 hpf decreased the expression of c/ebpa (C and D, arrowheads) and lpl (E and F, arrowheads), did not affect the
expression of pparg (G and H, arrowheads) and increased the expression of fabp11a (I and J, arrowheads).
(K) Lipid amounts are depicted for lipid categories that were significantly changed by exposure to 5 mMBADGE from 26–52 hpf. Lipid species concentrations are
shown in pmol/15 embryos (K). The amount of each individual lipid at a single time point in 5 mMBADGE-treated embryos was set relative to the level of that lipid
species in control embryos. *p < 0.05.
(L) A log2 ratio was then calculated for the signals of each lipid species. Red indicates an increase compared to the mean, green indicates a decrease and black
shows no change. Gray is displayed when there is no lipid present.
See also Figure S4.(Ravaux et al., 2007). Phospholipase A2 is responsible for pro-
ducing lysophospholipid species from phospholipids (D’Arrigo
and Servi, 2010). Therefore, it is reasonable to presume that in
our PPARg-inhibited embryos there may have been an1326 Cell Reports 14, 1317–1329, February 16, 2016 ª2016 The Authincrease in phospholipase A2 expression and activity that could
have the led to the increased levels of the lysophospholipid
species. Although the lysophospholipid data correlated to
results reported in a previous study (Ravaux et al., 2007), manyors
additional changes in the lipids in the BADGE-treated embryos
were identified in this project. Liquid chromatography-mass
spectrometry provides a promising tool for in depth
analyses intomany aspects of lipid biology, including pharmaco-
logical, disease, or metabolic studies, in an amenable model
organism.
EXPERIMENTAL PROCEDURES
Lipid Extraction
Lipids were extracted with dichloromethane:methanol (2:1) using the Folch
method (Folch et al., 1957). The organic phase was dried with nitrogen and
reconstituted in 50 ml of chloroform for thin layer chromatography (TLC).
Thin Layer Chromatography
Samples were run on silica gel 60 aluminum sheets (Merck Millipore). Twenty-
five microliters of samples and standards were spotted on the plate. TLC
plates were developed in a solution of 43 ml petroleum ether, 7 ml diethyl
ether, and 1 ml acetic acid. Standard 1 (Nu-chek Prep) contains equal parts
lecithin (1,2 distearoyl), cholesterol, oleic acid, triolein, and cholesteryl oleate.
Standard 2 (Nu-chek Prep) contains equal parts monoolein, diolein, triolein,
and methyl oleate. Positive controls were 0.5 ml BODIPY/oil stock dissolved
in 25 ml of chloroform. Non-fluorescent lipids were detected with KMnO4 stain
giving a pale orange color.
For complete experimental procedures, see the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.01.016.
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